Ubs Oncology Impact Fund L.P. Tcr2 Therapeutics Inc. (TCRR) insider trading activity

Ubs Oncology Impact Fund L.P. is > 10% Shareholder of TCR2 THERAPEUTICS INC.. Currently has a direct ownership of 0 shares of TCRR, which is worth approximately $0. The most recent transaction as insider was on Jun 01, 2023, when has been sold 3,370,982 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

UBS Oncology Impact Fund L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 01 2023	SELL Other acquisition or disposition	-	3,370,982 Reduced 100.0%	0 Common Stock
Feb 19 2019	BUY Open market or private purchase	$10,000,005 $15.0 p/Share	666,667 Added 16.51%	3,370,982 Common Stock
Feb 19 2019	BUY Conversion of derivative security	-	2,704,315 Added 50.0%	2,704,315 Common Stock

Also insider at

CGEM

Cullinan Oncology, Inc. Healthcare

> 10% Shareholder

HARP

Harpoon Therapeutics, Inc. Healthcare

> 10% Shareholder

ONCR

Oncorus, Inc. Healthcare

> 10% Shareholder

UOI